ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last1,541 to 1,560 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Parenteral Nutrition vs Enteral Nutrition: Post-procedural Sepsis129 of 2,912

108 of 2,912

0.7 points

-0.3 to 1.7

5,824NCT02512224

Comparison of Outcomes Between Parenteral and Enteral Nutrition

Parenteral Nutrition vs Enteral Nutrition: Mortality Calculated From Outcome Section From DPC Database at 30 Days114 of 2,912

89 of 2,912

0.9 points

-0.1 to 1.8

5,824NCT02512224

Comparison of Outcomes Between Parenteral and Enteral Nutrition

Parenteral Nutrition vs Enteral Nutrition: Mortality Calculated From Outcome Section From DPC Database at 14 Days114 of 2,912

89 of 2,912

0.9 points

-0.1 to 1.8

5,824NCT02512224

Comparison of Outcomes Between Parenteral and Enteral Nutrition

Canagliflozin (Experimental) vs Placebo (Placebo): deaths from any cause68 of 2,904

71 of 2,903

-0.1 points

-0.9 to 0.7

5,807NCT01989754

A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus

Canagliflozin (Experimental) vs Placebo (Placebo): serious adverse events714 of 2,904

775 of 2,903

-2.1 points

-4.4 to 0.1

5,807NCT01989754

A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus

Pre-Intervention: Patients Diagnosed With Conditions of Interest During Study Period vs Post-Intervention: Patients Diagnosed With Conditions of Interest During Study Period: Guideline-concordant Decision to Prescribe Antibiotics for Adult Pharyngitis1,464 of 2,032

2,492 of 3,764

5.8 points

3.4 to 8.3

5,796NCT06027593

Using Electronically Derived Automated Reports of Appropriate Antibiotic Use to Inform Stewardship Interventions

Pre-Intervention: Patients Diagnosed With Conditions of Interest During Study Period vs Post-Intervention: Patients Diagnosed With Conditions of Interest During Study Period: Guideline-concordant Antibiotic Use for Adults With Pharyngitis1,458 of 2,032

2,477 of 3,764

5.9 points

3.4 to 8.4

5,796NCT06027593

Using Electronically Derived Automated Reports of Appropriate Antibiotic Use to Inform Stewardship Interventions

Pre-Intervention: Patients Diagnosed With Conditions of Interest During Study Period vs Post-Intervention: Patients Diagnosed With Conditions of Interest During Study Period: 30-day Pharyngitis Outpatient Revisits (Emergency Department, Urgent Care, or Primary Care) in Adults291 of 2,032

578 of 3,764

-1.0 points

-2.9 to 0.9

5,796NCT06027593

Using Electronically Derived Automated Reports of Appropriate Antibiotic Use to Inform Stewardship Interventions

Pre-Intervention: Patients Diagnosed With Conditions of Interest During Study Period vs Post-Intervention: Patients Diagnosed With Conditions of Interest During Study Period: 30-day Deep Neck Space Infection Admission0 of 2,032

1 of 3,764

-0.0 points

-0.2 to 0.2

5,796NCT06027593

Using Electronically Derived Automated Reports of Appropriate Antibiotic Use to Inform Stewardship Interventions

Arm 1: Main Cohort: Group 1: Ad26.RSV.preF and RSV preF Protein (Protein Mixture) vs Arm 2: Main Cohort: Group 2: Placebo: Main Cohorts:Number of Participants With Serious Adverse Events (SAEs)203 of 2,891

196 of 2,891

0.2 points

-1.1 to 1.6

5,782NCT03982199

A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older

PDE5 Inhibitors vs Endothelin Receptor Antagonists: deaths from any cause327 of 2,888

407 of 2,888

-2.8 points

-4.5 to -1.1

5,776NCT05039086

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - PDE5

Cervarix Group vs Aluminium Hydroxide Group: serious adverse events291 of 2,881

269 of 2,871

0.7 points

-0.8 to 2.3

5,752NCT00294047

Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older

30% Oxygen vs 80% Oxygen: Number of Participants With Superficial SSI (Surgical Site Infection)183 of 2,853

150 of 2,896

1.2 points

0.0 to 2.5

5,749NCT01777568

Supplemental Oxygen in Colorectal Surgery: A Quality Improvement Project

30% Oxygen vs 80% Oxygen: deaths from any cause10 of 2,853

20 of 2,896

-0.3 points

-0.7 to 0.0

5,749NCT01777568

Supplemental Oxygen in Colorectal Surgery: A Quality Improvement Project

30% Oxygen vs 80% Oxygen: Number of Participants With One or More Composite Complications314 of 2,853

314 of 2,896

0.2 points

-1.5 to 1.8

5,749NCT01777568

Supplemental Oxygen in Colorectal Surgery: A Quality Improvement Project

30% Oxygen vs 80% Oxygen: serious adverse events314 of 2,853

314 of 2,896

0.2 points

-1.5 to 1.8

5,749NCT01777568

Supplemental Oxygen in Colorectal Surgery: A Quality Improvement Project

Cervarix Group vs Aluminium Hydroxide Group: Number of Subjects Reporting New Onset of Autoimmune Disease (NOADs).24 of 2,877

24 of 2,870

-0.0 points

-0.5 to 0.5

5,747NCT00294047

Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older

Cervarix Group vs Aluminium Hydroxide Group: Number of Subjects Reporting Medically Significant Conditions (MAEs).1,170 of 2,877

1,140 of 2,870

0.9 points

-1.6 to 3.5

5,747NCT00294047

Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older

Cervarix Group vs Aluminium Hydroxide Group: Number of Subjects Reporting Any AE/SAE Leading to Premature Discontinuation of the Study.28 of 2,877

14 of 2,870

0.5 points

0.0 to 1.0

5,747NCT00294047

Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older

Cervarix Group vs Aluminium Hydroxide Group: Number of Subjects Reporting New Onset of Chronic Disease (NOCDs).143 of 2,877

165 of 2,870

-0.8 points

-2.0 to 0.4

5,747NCT00294047

Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=78

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT02512224-774ba4de",
        "title": "Parenteral Nutrition vs Enteral Nutrition: Post-procedural Sepsis",
        "summary": "129 of 2912 against 108 of 2912; risk difference 0.7 points, 95% interval -0.3 to 1.7; NCT02512224, Comparison of Outcomes Between Parenteral and Enteral Nutrition",
        "record": "/library/comparisons/NCT02512224-774ba4de",
        "nct_id": "NCT02512224",
        "kind": "outcome",
        "participants": 5824,
        "risk_difference": {
          "value": 0.007211538461538464,
          "lower": -0.0029714610473166817,
          "upper": 0.017452996996872285
        },
        "group_1": "129 of 2,912",
        "group_2": "108 of 2,912",
        "difference": "0.7 points",
        "interval": "-0.3 to 1.7",
        "trial_title": "Comparison of Outcomes Between Parenteral and Enteral Nutrition"
      },
      {
        "id": "NCT02512224-931432c4",
        "title": "Parenteral Nutrition vs Enteral Nutrition: Mortality Calculated From Outcome Section From DPC Database at 30 Days",
        "summary": "114 of 2912 against 89 of 2912; risk difference 0.9 points, 95% interval -0.1 to 1.8; NCT02512224, Comparison of Outcomes Between Parenteral and Enteral Nutrition",
        "record": "/library/comparisons/NCT02512224-931432c4",
        "nct_id": "NCT02512224",
        "kind": "outcome",
        "participants": 5824,
        "risk_difference": {
          "value": 0.008585164835164836,
          "lower": -0.0008636105443717516,
          "upper": 0.018119721196091877
        },
        "group_1": "114 of 2,912",
        "group_2": "89 of 2,912",
        "difference": "0.9 points",
        "interval": "-0.1 to 1.8",
        "trial_title": "Comparison of Outcomes Between Parenteral and Enteral Nutrition"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=79",
  "request_id": "_Kn-q399jMaBB3VJ"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?